China’s National Medical Products Administration (NMPA) has approved the supplemental biologics license application (sBLA) for Cejemly (sugemalimab) alongside f 8 December 2023
South Africa's largest drugmaker Aspen Pharmacare has announced an agreement with newly-independent generics drugmaker Sandoz, related to its Chinese business. 7 December 2023
Swiss pharma giant Novartis is consolidating its commitment to radioligand therapies with the establishment of a second production site in China. 6 December 2023
Industry analyst GlobalData has highlighted the potential of CAR T-cell therapy advancements in China, noting a relative lack of partnerships with global pharma 30 November 2023
British pharma major AstraZeneca has established a new R&D center in Hong Kong, focused on research and development in areas including cell and gene therapies. 27 November 2023
Chinese biopharma Everest Medicines has won approval from China's National Medical Products Administration (NMPA) for Nefecon (budesonide) for the treatment of 24 November 2023
A new partnership in China will see German generics drugmaker STADA expand and bolster its distribution and promotion of cough and cold brands in the country. 23 November 2023